143 related articles for article (PubMed ID: 9541334)
41. Drug compliance and cognitive-behavioral therapy in schizophrenia.
Lecompte D
Acta Psychiatr Belg; 1995; 95(2):91-100. PubMed ID: 8525853
[TBL] [Abstract][Full Text] [Related]
42. The role of cognition in the risk--benefit and safety analysis of antipsychotic medication.
Borison RL
Acta Psychiatr Scand Suppl; 1996; 389():5-11. PubMed ID: 8985471
[TBL] [Abstract][Full Text] [Related]
43. Antipsychotic side-effect - potential risk of patients rejecting their treatments.
Dadić-Hero E; Ruzić K; Medved P; Tatalović-Vorkapić S; Graovac M
Psychiatr Danub; 2010 Mar; 22(1):105-7. PubMed ID: 20305602
[TBL] [Abstract][Full Text] [Related]
44. From darkness with courage...
Aldridge R
Nurs N Z; 1997 Oct; 3(9):21-2. PubMed ID: 9386466
[No Abstract] [Full Text] [Related]
45. Insight and adherence to medication in chronic schizophrenics.
Lin IF; Spiga R; Fortsch W
J Clin Psychiatry; 1979 Oct; 40(10):430-2. PubMed ID: 489521
[TBL] [Abstract][Full Text] [Related]
46. [Local monitoring center for clozapine (Leponex) treatment].
Bakken K; Bratlid T; Erlandsen C; Lingjaerde O; Nome S
Tidsskr Nor Laegeforen; 1998 Mar; 118(7):1076-8. PubMed ID: 9531833
[TBL] [Abstract][Full Text] [Related]
47. Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.
Fitton A; Benfield P
Pharmacoeconomics; 1993 Aug; 4(2):131-56. PubMed ID: 10146973
[TBL] [Abstract][Full Text] [Related]
48. Clozapine in the management of schizophrenia. Compliance no worse than with other neuroleptic drugs.
Wilson JD
BMJ; 1993 Jul; 307(6897):200. PubMed ID: 8102075
[No Abstract] [Full Text] [Related]
49. Clozapine: exploring clients' experiences of treatment.
McAllister M; Chatterton R
Aust N Z J Ment Health Nurs; 1996 Sep; 5(3):136-42. PubMed ID: 9079309
[TBL] [Abstract][Full Text] [Related]
50. Partial compliance with antipsychotics and its impact on patient outcomes.
Narasimhan M; Un Pae C; Masand N; Masand P
Int J Psychiatry Clin Pract; 2007; 11(2):102-11. PubMed ID: 24937555
[TBL] [Abstract][Full Text] [Related]
51. Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment.
Lisoway AJ; Chen CC; Zai CC; Tiwari AK; Kennedy JL
Schizophr Res; 2021 Jun; 232():112-124. PubMed ID: 34049235
[TBL] [Abstract][Full Text] [Related]
52. Atypical neuroleptics.
Pandarakalam JP
Hosp Med; 2000 Jan; 61(1):10-4. PubMed ID: 10735147
[TBL] [Abstract][Full Text] [Related]
53. Evaluation of the factors interfering with drug treatment compliance among Brazilian patients with schizophrenia.
Rosa MA; Marcolin MA; Elkis H
Braz J Psychiatry; 2005 Sep; 27(3):178-84. PubMed ID: 16224604
[TBL] [Abstract][Full Text] [Related]
54. Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.
Awad AG
CNS Drugs; 2019 Jan; 33(1):1-8. PubMed ID: 30511350
[TBL] [Abstract][Full Text] [Related]
55. Long-term follow-up of clozapine prescribing.
Gee SH; Shergill SS; Taylor DM
J Psychopharmacol; 2018 May; 32(5):552-558. PubMed ID: 29692222
[TBL] [Abstract][Full Text] [Related]
56. Determination of clozapine in serum of patients with schizophrenia as a measurement of medication compliance.
Mennickent S; Sobarzo A; Vega M; de Diego M; Godoy G; Rioseco P; Saavedra L
Int J Psychiatry Clin Pract; 2010 Mar; 14(1):41-6. PubMed ID: 24917231
[TBL] [Abstract][Full Text] [Related]
57. Patients' and relatives' assessment of clozapine treatment.
Angermeyer MC; Löffler W; Müller P; Schulze B; Priebe S
Psychol Med; 2001 Apr; 31(3):509-17. PubMed ID: 11305859
[TBL] [Abstract][Full Text] [Related]
58. Refill patterns of atypical and conventional antipsychotic medications at a national retail pharmacy chain.
Vanelli M; Burstein P; Cramer J
Psychiatr Serv; 2001 Sep; 52(9):1248-50. PubMed ID: 11533402
[TBL] [Abstract][Full Text] [Related]
59. Treatment adherence and long-term outcomes.
Kane JM
CNS Spectr; 2007 Oct; 12(10 Suppl 17):21-6. PubMed ID: 17934386
[TBL] [Abstract][Full Text] [Related]
60. New Developments in the Treatment of Schizophrenia: An Expert Roundtable.
Kantrowitz JT; Correll CU; Jain R; Cutler AJ
Int J Neuropsychopharmacol; 2023 May; 26(5):322-330. PubMed ID: 36932673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
